Zieo Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 25-07-2024
- Paid Up Capital ₹ 1.00 M
as on 25-07-2024
- Company Age 9 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.25 Cr
as on 25-07-2024
- Revenue 31.11%
(FY 2023)
- Profit 19.60%
(FY 2023)
- Ebitda 20.06%
(FY 2023)
- Net Worth 55.57%
(FY 2023)
- Total Assets 64.27%
(FY 2023)
About Zieo Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.25 Cr.
Prasanth Koottakkallil, Ambazhathingal Noufal, Dileepkumar Thottungal, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24233KA2015PTC083999
- Company No.
083999
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Nov 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Zieo Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narayanankutty Vinod  | Managing Director | 09-Nov-2015 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Prasanth Koottakkallil | Director | 30-Jul-2016 | Current |
| Ambazhathingal Noufal | Director | 30-Jul-2016 | Current |
| Dileepkumar Thottungal | Director | 30-Jul-2016 | Current |
| Manikandan Vadikeettil | Director | 20-Jul-2016 | Current |
Financial Performance of Zieo Pharmaceuticals.
Zieo Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 31.11% increase. The company also saw a substantial improvement in profitability, with a 19.6% increase in profit. The company's net worth Soared by an impressive increase of 55.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zieo Pharmaceuticals?
In 2023, Zieo Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The South Indian Bank Limited Creation Date: 02 Dec 2023 | ₹7.50 M | Open |
Hdfc Bank Limited Creation Date: 09 Jun 2022 | ₹5.00 M | Open |
How Many Employees Work at Zieo Pharmaceuticals?
Unlock and access historical data on people associated with Zieo Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zieo Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zieo Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
